Should You Buy the Vicore Pharma Holding AB IPO? Here's the Setup
Vicore Pharma Holding AB American Depositary Shares are expected to list on NASDAQ on 2026-07-02, with the price range not disclosed yet. This is a U.S. dual listing, not a traditional cash-raising IPO, so the main question is whether the story around buloxibutid is strong enough to attract U.S. investors. The bull case is a first-in-class IPF drug in a large unmet market; the bear case is a clinical-stage company still years from commercialization.
Vicore Pharma Holding AB American Depositary Shares are expected to list on NASDAQ on 2026-07-02, with the price range not disclosed yet. This is a U.S. dual listing, not a traditional cash-raising IPO, so the main question is whether the story around buloxibutid is strong enough to attract U.S. investors. The bull case is a first-in-class IPF drug in a large unmet market; the bear case is a clinical-stage company still years from commercialization.
Quick Facts
Expected listing date: July 2, 2026
Exchange: NASDAQ
Proposed symbol: VCRE
Status: Expected
Company Overview
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company focused on respiratory and fibrotic diseases, with idiopathic pulmonary fibrosis, or IPF, at the center of the story. Its lead program is buloxibutid, a first-in-class oral small-molecule angiotensin II type 2 receptor agonist. The company says buloxibutid has received Orphan Drug and Fast Track designations from the FDA and is being tested in the global 52-week Phase 2b ASPIRE trial.
The business is still early and not commercial. Vicore says it has no approved products and has never generated revenue from product sales. Its operations mainly consist of business support services, while R&D is primarily conducted in Vicore Pharma AB. The company is headquartered in Stockholm, Sweden, with offices in Copenhagen and Cambridge, Massachusetts, and it does not own or operate research or production facilities.
The market backdrop is attractive but competitive. Vicore’s materials describe the global IPF population as about 3,000,000 and the market as $10B+ with an estimated 10% to 15% CAGR. That is a meaningful opportunity, but it is also a space with entrenched therapies and high clinical risk, including Ofev and Esbriet as the established standards of care.
Why They're Going Public
Vicore’s SEC registration statement says the use of proceeds is “Not applicable,” which fits the structure here: this is a U.S. dual listing and reporting-company registration, not a traditional capital raise. Vicore also said in its May 22, 2026 release that the U.S. listing is being pursued with no concurrent financing or share offering planned.
The practical goal is visibility and access. A Nasdaq listing can broaden the investor base, improve trading liquidity, and give the company a stronger U.S. profile as it advances buloxibutid through later-stage development. For a clinical-stage biotech, that matters because the market often rewards companies that can keep financing optionality open while they build data around a lead asset.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
Vicore’s 2025 revenue was SEK 3.817 million, down sharply from SEK 109.346 million in 2024, a decline of about 96.5% year over year. The company says 2024 revenue included a SEK 104.2 million upfront payment plus SEK 5.1 million of reimbursements under the Nippon Shinyaku agreement, while there were no revenues in 2023. This is not a recurring revenue story; it is a development-stage biotech with lumpy collaboration income.
Losses remain substantial and are widening as R&D scales. Operating loss was SEK 452.386 million in 2025 versus SEK 194.189 million in 2024, and net loss attributable to shareholders was SEK 477.474 million versus SEK 168.634 million. R&D expense rose to SEK 390.348 million from SEK 249.263 million, which is consistent with a company pushing a lead program through clinical development. On the balance sheet, Vicore reported SEK 578.147 million in cash and cash equivalents and SEK 588.591 million in short-term investments as of Dec. 31, 2025, for SEK 1.1668 billion combined. The company had 39 employees as of March 1, 2026.
Risk Factors
The biggest risk is concentration: Vicore is substantially dependent on buloxibutid. If the drug fails in clinical development, runs into safety issues, is delayed, or does not win approval, the company’s core thesis weakens materially. That is the central biotech risk here, and it is amplified by the fact that Vicore has no approved products and no product sales history.
Commercialization risk is also real even if the data are positive. Vicore would still need to prove it can compete against established IPF therapies, secure reimbursement, and eventually build sales and marketing infrastructure. The filing also flags intellectual property protection, patent litigation, regulatory risk, and the possibility that additional capital may be needed to commercialize if approved. Because this is a dual listing rather than a new-money IPO, there is no traditional IPO lockup story to anchor near-term supply, but shareholders should still watch the stock’s trading dynamics closely once it starts.
Comparable Public Companies
The closest public comp is United Therapeutics (UTHR), which has IPF exposure through inhaled treprostinil and has been one of the stronger names in the pulmonary space over the last 6 to 12 months. Vicore is much earlier and smaller than UTHR, but both sit in the broader pulmonary-fibrosis and rare-lung-disease conversation.
For the incumbent IPF market, the relevant commercial references are Ofev and Esbriet, though those are not clean U.S.-listed standalone comps in the same way. Vicore’s pitch is that buloxibutid could offer a more disease-modifying mechanism than current standards of care, which is the kind of claim that can matter if later-stage data support it. The company is also competing indirectly with the broader biotech sector for capital, where investors tend to reward clear clinical catalysts and penalize long timelines.
The comp set is mixed rather than uniformly hot. UTHR has been strong, which suggests the pulmonary theme can still attract capital when the story is credible, but early-stage biotech remains highly data-dependent and valuation-sensitive. In practical terms, this is a sector where the market will pay up for convincing clinical differentiation, but not for platform potential alone.
Verdict
The setup favors a watchlist approach until the market sees how Vicore’s U.S. listing is received and whether investors treat buloxibutid as a credible late-stage IPF opportunity. Because there is no concurrent financing or share offering planned, the key question is not dilution from the listing itself; it is whether the dual listing helps re-rate the story around a first-in-class asset in a large unmet market.
This matters now because IPF remains a high-need area with a $10B+ market and limited treatment options, and Vicore is trying to bring a differentiated mechanism to a space that already has commercial incumbents. The IPO window for biotech is selective, not broad, so the narrative has to carry the deal: first-in-class science, FDA designations, and a clear clinical catalyst path. Shareholders should watch the ASPIRE trial, the company’s cash runway, and whether U.S. trading brings in enough demand to validate the listing.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
